Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Sickle-Cell Disease
Interventions
DRUG

Sevuparin

The Drug Product sevuparin solution for IV infusion

OTHER

Placebo

Placebo for IV infusion

Trial Locations (20)

Unknown

Salmaniya Hospital, Kingdom of Bahrain, Manama

Salmaniya Medical Complex, Bahrain, Manama

Annotto Bay Hospital, Annotto Bay

Kingston Public Hospital, Kingston

University Hospital of the West Indies, Kingston

Winchester Surgical and Medical Institute, Kingston

Mandeville Regional Hospital, Mandeville

May Pen Public Hospital Clarendon, May Pen

Cornwall Regional Hospital, Jamaica, Montego Bay

American University of Beirut Medical Center, Beirut, Cairo street, Beirut, Lebanon, Beirut

Nini Hospital, Tripoli

Dept of Haematology, Amsterdam

Erasmus MC, Rotterdam

Sultan Qaboos University Hospital Alkhodh, Oman, Muscat

Sultan Qaboos University, Muscat

King Fahd Medical City, As Sulimaniyah, Riyadh Saudiarabien, Riyadh

King Saud University, Riyadh, Saudiarabien, Riyadh

Mersin University Faculty of Medicine, Adana

Cukurova University Faculty Of Medicine Tıp Fakültesi, Adana

Dr Antmen, Adana

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ergomed

INDUSTRY

lead

Modus Therapeutics AB

INDUSTRY